• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

    3/23/23 4:30:00 PM ET
    $CLVT
    $CNTA
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLVT alert in real time by email

    Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board

    LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.

    (PRNewsfoto/Clarivate Analytics)

    Jonathan Gear, Chief Executive Officer, Clarivate said: "I'm very pleased to announce the appointment of Gordon who has been a trusted and valued member of our Executive Leadership Team since he came to Clarivate from CPA Global as part of our acquisition in 2020. In this newly created role, he will be responsible for accelerating the growth of our IP segment empowering customers to establish, protect and manage their IP.

    Based on my experience working with him over the last eight months and the work we've done this year to align the organization, I'm confident that he will be instrumental to how we capitalize on product and service innovation to deliver organic growth. This is the first of our presidential appointments and we look forward to providing updates on further appointments in due course."

    Samson joined Clarivate in October 2020 with the acquisition of CPA Global, having joined CPA Global in 2014 as Chief Operating Officer. During the last three years with Clarivate, Samson has made significant contributions, helping transform the Company's APAC region and bringing together the Company's entire product portfolio to offer customers a full range of enriched data, insights, analytics and workflow solutions. He has a long and successful track record of driving organizational transformation and growth in the IP industry and beyond, having held senior executive roles with both operating and P&L accountability for more than 20 years.

    Andy Snyder, Chairman of the Board, Clarivate commented: "We look forward to Dr. Saha joining our Board. He will bring a great deal of experience in the pharmaceutical and biotech industries and his guidance will provide valuable insights and perspective, especially as we continue to execute on our growth strategy in the Life Sciences & Healthcare segment."

    Dr. Saha is a physician-scientist, pharmaceutical executive, and biotech entrepreneur dedicated to discovering and developing novel life-changing medicines. He is notable for leading the development and demonstrating human effectiveness of two innovative cancer drugs, an ERK kinase inhibitor (Ulixertinib) and an oncolytic immunotherapy (C. novyi-NT). He is currently CEO of Centessa Pharmaceuticals (NASDAQ:CNTA), a global pharma company. Prior to Centessa, Dr. Saha was a Senior Vice President of R&D and Global Head of Translational Medicine for all disease areas at Bristol Myers Squibb. Other past roles include Venture Partner at Atlas Venture, a VC firm in Cambridge MA, Chief Executive Officer at Delinia, Chief Medical Officer of Synlogic, a management consultant at McKinsey & Company, and head of the New Indications Discovery Unit at Novartis. He is an associate member and Global Clinical Scholar at Harvard Medical School, holds an MD and PhD in medicine and cancer genetics from The Johns Hopkins School of Medicine, an MSc in biophysics from the University of Oxford and a BSc in biochemistry from Caltech.

    About Clarivate

    Clarivate™ is a leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit clarivate.com.

    Investor Relations Contact

    Mark Donohue, Head of Investor Relations, [email protected], +1 (215) 243 2202

    Media Contact

    Amy Bourke-Waite, Senior Director, Corporate Communications, [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-announces-gordon-samson-as-president-intellectual-property-and-nominates-dr-saurabh-saha-as-new-independent-director-301780121.html

    SOURCE Clarivate Plc

    Get the next $CLVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLVT
    $CNTA

    CompanyDatePrice TargetRatingAnalyst
    Centessa Pharmaceuticals plc
    $CNTA
    5/28/2025$35.00Buy
    Needham
    Centessa Pharmaceuticals plc
    $CNTA
    5/8/2025$30.00Buy
    Chardan Capital Markets
    Centessa Pharmaceuticals plc
    $CNTA
    3/31/2025$38.00Overweight
    Piper Sandler
    Centessa Pharmaceuticals plc
    $CNTA
    1/7/2025Buy
    TD Cowen
    Clarivate Plc
    $CLVT
    11/6/2024Outperform → Mkt Perform
    William Blair
    Centessa Pharmaceuticals plc
    $CNTA
    9/20/2024$11.00 → $26.00Equal-Weight → Overweight
    Morgan Stanley
    Centessa Pharmaceuticals plc
    $CNTA
    9/19/2024$33.00Buy
    B. Riley Securities
    Centessa Pharmaceuticals plc
    $CNTA
    7/18/2024$14.00Outperform
    Oppenheimer
    More analyst ratings

    $CLVT
    $CNTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Goyal Arjun bought $5,865,242 worth of Ordinary Shares (462,585 units at $12.68) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      5/19/25 5:49:01 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Snyder Andrew Miles bought $989,024 worth of Ordinary Shares (237,176 units at $4.17) (SEC Form 4)

      4 - CLARIVATE PLC (0001764046) (Issuer)

      3/18/25 4:56:10 PM ET
      $CLVT
      EDP Services
      Technology
    • Director Bomba Jane L Okun bought $200,492 worth of Ordinary Shares (49,750 units at $4.03) (SEC Form 4)

      4 - CLARIVATE PLC (0001764046) (Issuer)

      3/14/25 4:14:29 PM ET
      $CLVT
      EDP Services
      Technology

    $CLVT
    $CNTA
    Financials

    Live finance-specific insights

    See more
    • Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

      Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IHORX142 on track to initiate first-in-human studies for the treatment of neurological and neurodegenerative disorders with clinical data in acutely sleep-deprived healthy volunteers planned for this yearORX489 advancing in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, May 14, 20

      5/14/25 7:00:53 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarivate Reports First Quarter 2025 Results

      — Accelerated recurring organic revenue growth — — Reaffirmed 2025 Outlook — — Repurchased $50 million ordinary shares — LONDON, April 29, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2025. Total revenues for the first quarter of 2025 was $593.7 million, compared to total revenues of $621.2 million for the first quarter of 2024. Organic revenues for the first quarter of 2025 increased 0.3%, compared to the first quarter of 202

      4/29/25 6:00:00 AM ET
      $CLVT
      EDP Services
      Technology
    • Clarivate to Report First Quarter 2025 Results on April 29, 2025

      LONDON, April 2, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the first quarter 2025 before the market opens on Tuesday, April 29, 2025. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com. The Company will host a conference call and webcast at 9:00 AM Eastern Time on Tuesday, April 29, 2025 to review the results. The webcast is open to all interested

      4/2/25 8:05:00 AM ET
      $CLVT
      EDP Services
      Technology

    $CLVT
    $CNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Clarivate Plc

      SC 13G/A - CLARIVATE PLC (0001764046) (Subject)

      12/5/24 10:02:09 AM ET
      $CLVT
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

      SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

      11/14/24 5:43:48 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

      SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

      11/14/24 4:20:32 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVT
    $CNTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Weinhoff Gregory M exercised 10,000 units of Ordinary Shares at a strike of $3.85 and sold $128,225 worth of Ordinary Shares (10,000 units at $12.82) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      5/27/25 6:31:36 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Saha Saurabh exercised 55,000 units of Ordinary Shares at a strike of $3.85 and sold $699,110 worth of Ordinary Shares (55,000 units at $12.71) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      5/20/25 5:44:05 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Goyal Arjun bought $5,865,242 worth of Ordinary Shares (462,585 units at $12.68) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      5/19/25 5:49:01 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVT
    $CNTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

      BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.  "Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year," said Saurabh Saha MD

      1/8/25 7:05:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

      BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen

      6/10/24 7:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Announces Additions to Senior Leadership Team

      BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody® technology platform. "We a

      10/3/23 8:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVT
    $CNTA
    SEC Filings

    See more
    • Centessa Pharmaceuticals plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Centessa Pharmaceuticals plc (0001847903) (Filer)

      5/29/25 8:08:42 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Centessa Pharmaceuticals plc

      DEFA14A - Centessa Pharmaceuticals plc (0001847903) (Filer)

      5/28/25 9:15:45 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Centessa Pharmaceuticals plc

      144 - Centessa Pharmaceuticals plc (0001847903) (Subject)

      5/27/25 4:02:14 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVT
    $CNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham initiated coverage on Centessa Pharmaceuticals with a new price target

      Needham initiated coverage of Centessa Pharmaceuticals with a rating of Buy and set a new price target of $35.00

      5/28/25 9:07:36 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Centessa Pharmaceuticals with a new price target

      Chardan Capital Markets initiated coverage of Centessa Pharmaceuticals with a rating of Buy and set a new price target of $30.00

      5/8/25 8:28:10 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Centessa Pharmaceuticals with a new price target

      Piper Sandler initiated coverage of Centessa Pharmaceuticals with a rating of Overweight and set a new price target of $38.00

      3/31/25 8:13:04 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVT
    $CNTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

      BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2025 Global Healthcare Conference Date: June 4, 2025Fireside Chat: 11:40 AM ET Event: Goldman Sachs 46th Annual Global Healthcare ConferenceDate: June 10, 2025Fireside Chat: 9:20 AM ET Access to the live webcasts of these events, as well as archived recordings, will be available under the "Events and Publications" tab on the investor

      5/19/25 8:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarivate Launches AI-based RiskMark to Accelerate Trademark Conflict Assessments

      New AI-based solution empowers trademark professionals to evaluate trademark risk and generate evidence-backed arguments with speed, ease, and confidence LONDON, May 19, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of RiskMark, an AI-powered solution combining global CompuMark trademark data and Darts-ip litigation data to evaluate trademark risk. Leveraging 172.5 million trademark records spanning 188 jurisdictions and over 5 million global court and administrative records, RiskMark combi

      5/19/25 3:00:00 AM ET
      $CLVT
      EDP Services
      Technology
    • Clarivate Report Reveals Top Trademark Portfolios

      Procter & Gamble, Nestlé, Apple, L'Oréal, Novartis, LG Electronics and Unilever among the largest portfolio owners in most registers LONDON, May 15, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the Trademark filing trends 2025 report, analyzing ten key trademark registers worldwide: the United States (U.S.), Canada, the United Kingdom (U.K.), the European Union (EU), France, Germany, India, Mainland China, Japan, and Australia. The report reveals the top 20 largest local and foreign-based trademark portfolios in each region and the law firms managing the largest trademark portfolios.

      5/15/25 3:00:00 AM ET
      $CLVT
      EDP Services
      Technology